01—Abstract
Summary
Summary of the 8-K filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc. (MRK) reported strong third-quarter 2026 financial results, driven by continued robust sales growth in its oncology and animal health segments, alongside contributions from other key products like WINREVAIR.
Total worldwide sales reached $18.1 billiona, a 5% increase year-over-year, with KEYTRUDA and KEYTRUDA QLEX sales showing a significant 6% rise to $8.6 billion. WINREVAIR demonstrated exceptional growth, soaring by 93% to $694 million.
The company also highlighted substantial progress in its diverse pipeline, particularly in oncology, with key data presentations at the ESMO Congress 2026 and regulatory milestones such as the U.S. FDA's acceptance of a priority review for sacituzumab tirumotecan (sac-TMT) in endometrial cancer. Merck has narrowed and raised its full-year 2026 financial outlook, now expecting sales between $66.8 billionb and $67.3 billion and non-GAAP EPS between $2.77 and $2.82, reflecting confidence in its ongoing growth trajectory and pipeline advancements.
02—Key points
Key Highlights
- Total worldwide sales reached $18.1 billion, a 5% increase year-over-year (4% excluding foreign exchange).
- KEYTRUDA and KEYTRUDA QLEX sales grew 6% to $8.6 billion, driven by strong global uptake in earlier-stage indications and higher demand in metastatic indications.
- WINREVAIR sales more than doubled, increasing 93% to $694 million, fueled by strong demand and international market launches.
- Animal Health sales grew 4% to $1.7 billion, supported by both livestock and companion animal product portfolios.
- The company presented pivotal Phase 3 data at ESMO 2026 for its oncology pipeline, including sacituzumab tirumotecan (sac-TMT) and a combination therapy with KEYTRUDA and Moderna's mRNA-4157 for melanoma.
- Merck raised and narrowed its full-year 2026 sales guidance to $66.8 billion - $67.3 billion and its non-GAAP EPS guidance to $2.77 - $2.82.
- The U.S. FDA accepted a Biologics License Application (BLA) for sac-TMT for endometrial cancer with a Priority Review designation.
03—Questions
Frequently Asked Questions
What were the key drivers of Merck's sales growth in the third quarter of 2026?
Sales growth was primarily driven by the strong performance of KEYTRUDA/KEYTRUDA QLEX and WINREVAIR, both in oncology, as well as continued strength in Animal Health. Growth in GARDASIL/GARDASIL 9 and WELIREG also contributed positively. While some products like JANUVIA/JANUMET and BRIDION saw declines due to generic competition, the overall portfolio demonstrated resilience and expansion.
What significant pipeline updates were provided in the filing?
Merck highlighted substantial progress in its oncology pipeline, presenting key Phase 3 data at the ESMO Congress 2026 for sacituzumab tirumotecan (sac-TMT) in endometrial cancer and for an investigational cancer vaccine in melanoma in collaboration with Moderna. Regulatory milestones include the U.S. FDA's acceptance of a priority review for sac-TMT. The company also reported positive Phase 2b results for its immunology candidate, tulelisokibart, and presented one-year data for remigromig in diabetic macular edema.
How has Merck adjusted its full-year 2026 financial outlook?
Merck has narrowed and raised its full-year 2026 financial outlook. The company now expects worldwide sales to be between $66.8 billion and $67.3 billion, an increase from the previous range. The non-GAAP EPS outlook has also been raised and narrowed to a range of $2.77 to $2.82. This updated guidance incorporates a new one-time charge of $0.12 per share related to a global license agreement with SciBrunch.
Were there any significant expenses or charges impacting the reported earnings?
Both GAAP and non-GAAP EPS for the third quarter of 2026 include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch. Additionally, the full-year outlook includes significant charges related to acquisitions of Cidara Therapeutics ($3.62 per share) and Terns Pharmaceuticals ($2.31 per share).
04—Continue